Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., … Massaro, J. M. (2014). Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study. In CIRCULATION (Vol. 130, pp. 2107–2107). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.

Mauri, Laura, Dean J. Kereiakes, Robert W. Yeh, Priscilla Driscoll-Shempp, Donald E. Cutlip, Philippe G. Steg, Eugene Braunwald, et al. “Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study.” In CIRCULATION, 130:2107–2107. LIPPINCOTT WILLIAMS & WILKINS, 2014.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2014. p. 2107–2107.

Mauri, Laura, et al. “Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study.” CIRCULATION, vol. 130, no. 23, LIPPINCOTT WILLIAMS & WILKINS, 2014, pp. 2107–2107.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller JB, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Lee PNV, Rinaldi MJ, Massaro JM. Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2014. p. 2107–2107.